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BACKGROUND
Randomized trials have shown that the transplantation of filgrastim-mobilized 
peripheral-blood stem cells from HLA-identical siblings accelerates engraftment but 
increases the risks of acute and chronic graft-versus-host disease (GVHD), as com-
pared with the transplantation of bone marrow. Some studies have also shown that 
peripheral-blood stem cells are associated with a decreased rate of relapse and im-
proved survival among recipients with high-risk leukemia.
METHODS
We conducted a phase 3, multicenter, randomized trial of transplantation of periph-
eral-blood stem cells versus bone marrow from unrelated donors to compare 2-year 
survival probabilities with the use of an intention-to-treat analysis. Between March 
2004 and September 2009, we enrolled 551 patients at 48 centers. Patients were 
randomly assigned in a 1:1 ratio to peripheral-blood stem-cell or bone marrow trans-
plantation, stratified according to transplantation center and disease risk. The me-
dian follow-up of surviving patients was 36 months (interquartile range, 30 to 37).
RESULTS
The overall survival rate at 2 years in the peripheral-blood group was 51% (95% 
confidence interval [CI], 45 to 57), as compared with 46% (95% CI, 40 to 52) in the 
bone marrow group (P = 0.29), with an absolute difference of 5 percentage points 
(95% CI, −3 to 14). The overall incidence of graft failure in the peripheral-blood group 
was 3% (95% CI, 1 to 5), versus 9% (95% CI, 6 to 13) in the bone marrow group 
(P = 0.002). The incidence of chronic GVHD at 2 years in the peripheral-blood group 
was 53% (95% CI, 45 to 61), as compared with 41% (95% CI, 34 to 48) in the bone 
marrow group (P = 0.01). There were no significant between-group differences in the 
incidence of acute GVHD or relapse.
CONCLUSIONS
We did not detect significant survival differences between peripheral-blood stem-cell 
and bone marrow transplantation from unrelated donors. Exploratory analyses of 
secondary end points indicated that peripheral-blood stem cells may reduce the risk 
of graft failure, whereas bone marrow may reduce the risk of chronic GVHD. 
(Funded by the National Heart, Lung, and Blood Institute–National Cancer Institute 
and others; ClinicalTrials.gov number, NCT00075816.)
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In the early days of allogeneic hema-topoietic stem-cell transplantation, the only graft source available was bone marrow har-
vested from the pelvis of a donor under anesthe-
sia. When studies showed that an increased dose 
of bone marrow cells correlated with more robust 
hematopoietic engraftment and lower mortality 
from infectious complications, transplantation 
centers began to use filgrastim-stimulated pe-
ripheral blood, which has a much higher content 
of blood progenitor cells than bone marrow, al-
though there was concern that the higher T-cell 
content might increase the risk of graft-versus-
host disease (GVHD).1-5 Several large, random-
ized trials of transplantation between HLA-iden-
tical siblings showed that peripheral-blood stem 
cells resulted in better engraftment but increased 
the risk of acute and chronic GVHD.4-11 Some 
studies showed a decreased rate of relapse and 
better survival with peripheral-blood stem cells, as 
compared with bone marrow, especially among 
patients with high-risk blood-cell cancers. How-
ever, the results obtained with transplants from 
HLA-identical siblings may not be applicable to 
transplants from unrelated donors, given the 
greater genetic diversity and, therefore, greater 
risk of GVHD in the unrelated recipient, even if 
the donor and recipient are fully HLA-matched.
Over the past decade, the use of peripheral-
blood stem cells has increased and now accounts 
for 75% of stem-cell transplants from unrelated 
adult donors, without clinical data to support this 
shift.12 A large observational study of unrelated-
donor transplants showed higher rates of acute 
and chronic GVHD with peripheral-blood stem 
cells than with bone marrow and no improve-
ment in survival.13 To determine the effects 
of graft source for unrelated-donor transplants, 
we performed a randomized trial comparing out-




The study was an open-label, phase 3, multicenter, 
randomized trial conducted by the Blood and 
Marrow Transplant Clinical Trials Network. Ran-
domization was performed in a 1:1 ratio, with the 
use of random block sizes, and was stratified ac-
cording to transplantation center and disease risk. 
The target enrollment was 550 donor–recipient 
pairs. The primary end point was 2-year survival 
as assessed by means of an intention-to-treat anal-
ysis. Prespecified secondary end points included 
post-transplantation incidences of neutrophil and 
platelet engraftment, graft failure, acute and chron-
ic GVHD, relapse, and infections. Other end points 
included adverse events, immune reconstitution, 
time to discontinuation of immunosuppressive 
therapy, and quality of life. This article focuses on 
the primary end point and clinical secondary end 
points. Analyses of immune reconstitution and 
quality of life are ongoing.
Enrollment began on March 31, 2004, and 
ended on September 9, 2009. The analysis included 
data collected as of November 15, 2011. The me-
dian follow-up of surviving patients is 36 months 
(interquartile range, 30 to 37). Patients were fol-
lowed in the study for 3 years, with a late analy-
sis at 5 years planned with the use of data from 
the Center for International Blood and Marrow 
Transplant Research, which tracks the outcomes 
of all allogeneic transplantations in the United 
States.
PATIENTS
Eligible patients were less than 66 years of age and 
were planning to undergo transplantation for acute 
leukemia, myelodysplasia, chronic myeloid or 
myelomonocytic leukemia, or myelofibrosis. 
These diseases accounted for approximately 75% 
of unrelated-donor transplantations in the Unit-
ed States during the study period. Exclusion cri-
teria were donor-specific anti-HLA antibodies, 
prior allogeneic or autologous transplantation, 
human immunodeficiency virus infection, preg-
nancy or breast-feeding, cardiac insufficiency or 
coronary artery disease requiring treatment, ac-
tive infection, or concomitant enrollment in a 
phase 1 study. Additional exclusion criteria were a 
serum level of creatinine, bilirubin, alanine ami-
notransferase, or aspartate aminotransferase that 
was greater than two times the upper limit of the 
normal range, as well as a forced vital capacity, 
forced expiratory volume in 1 second, or diffus-
ing capacity of the lung for carbon monoxide that 
was less than 50% of the predicted value.
TREATMENT
The protocol required DNA typing of the patient 
and donor at intermediate resolution for HLA-A, 
B, and C and at high resolution for DRB1, as well 
as matching for five or six of the six HLA-A, B, 
and DRB1 antigens. All donors and recipients gave 
written informed consent before enrollment. Bone 
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marrow cells were collected from the donors by 
means of standard procedures. Peripheral-blood 
stem-cell donors were prescribed filgrastim (at the 
North American centers) or lenograstim (at the 
German centers) at a dose of 10 μg per kilogram 
of body weight per day for 5 days and underwent 
a single large-volume apheresis on day 5 or two 
smaller-volume apheresis procedures on days 5 and 
6. Bone marrow or peripheral-blood stem cells 
were not T-cell–depleted or cryopreserved before 
transplantation. No blinding was attempted.
Patients received one of four conditioning regi-
mens (cyclophosphamide and total-body irradia-
tion; cyclophosphamide and busulfan; fludarabine, 
busulfan, and antithymocyte globulin; or fludara-
bine and melphalan), with the minimum dose of 
each agent defined in the protocol (Table 1). The 
cyclophosphamide-containing regimens are my-
eloablative, whereas the fludarabine-containing 
regimens are reduced-intensity conditioning regi-
mens. Patients received one of two GVHD-prophy-
laxis regimens (tacrolimus and methotrexate, or 
cyclosporine and methotrexate), with or without 
additional agents. Both the conditioning and 
GVHD-prophylaxis regimens had to be specified 
before randomization. Supportive care and treat-
ment for GVHD were provided according to insti-
tutional standards. A committee of investigators 
who were unaware of the study assignments re-
viewed all case records, focusing on causes of 
death, relapse, acute and chronic GVHD, and graft 
failure. The protocol is available with the full text 
of this article at NEJM.org and on a public web-
site (www.bmtctn.net).
A protocol review committee appointed by the 
National Heart, Lung, and Blood Institute ap-
proved the research protocol, which was also ap-
proved by local institutional review boards and 
ethics committees. All authors vouch for the ac-
curacy and completeness of the reported data and 
analyses and for the adherence of the study to the 
protocol. The data and safety monitoring board 
appointed by the National Heart, Lung, and Blood 
Institute also reviewed the analyses.
STATISTICAL ANALYSIS
After accounting for an anticipated 5% of patients 
not undergoing transplantation, we calculated 
that the study would have 80% power to detect a 
difference of 12.5 percentage points in the 2-year 
survival rate between the two study groups (35.0% 
and 47.5%), with the use of a chi-square test and 
a two-sided alpha level of 5%. There was no pre-
defined anticipated direction of the survival dif-
ference between the two treatment groups. All 
patients who underwent randomization were in-
cluded in the primary, intention-to-treat analysis 
of overall survival. Survival times were calculated 
from the date of randomization.
The primary analysis was planned as a point-
wise comparison of overall survival at 2 years 
rather than as a log-rank test because of concerns 
about nonproportional hazards between the two 
groups. However, the final analyses did not show 
violations of hazard proportionality, and therefore, 
results of the Cox model are also presented. The 
primary comparison of 2-year survival was per-
formed with the use of a stratified binomial com-
parison (Mantel–Haenszel test), stratified accord-
ing to transplantation center and disease risk. 
Kaplan–Meier survival curves were constructed 
for each group.
For analyses of the secondary end points, data 
on transplantation-related events were collected 
only for patients who underwent transplantation, 
and event times were calculated from the date of 
transplantation. There was no explicit adjustment 
for multiple testing of secondary end points, and 
since the primary statistical hypothesis was not 
rejected, all the secondary analyses are considered 
exploratory. Results are presented according to 
study group. The rates of neutrophil and platelet 
engraftment, graft failure, acute GVHD, chronic 
GVHD, death in the absence of relapse, and re-
lapse were compared between the two groups with 
the use of a stratified log-rank test that treated 
relapse as a competing event for death in the ab-
sence of relapse and treated death as a competing 
risk for all other end points. Cumulative incidence 
curves were estimated for each group.14 Chronic 
GVHD was classified as limited or extensive, as 
previously reported,15 because the study protocol 
was written before the National Institutes of 
Health workshop that redefined diagnostic and 
staging criteria for chronic GVHD.16
However, chronic GVHD did not include cases 
with sole manifestations of late acute GVHD that 
occurred more than 100 days after transplanta-
tion. Inclusion of these late cases in the analyses 
of acute GVHD did not change the results (data 
not shown). The probabilities of being alive and 
free of immunosuppressive treatment at 2 years 
were compared between the two study groups 
with the use of the chi-square test. Two-year rates 
of overall survival and disease-free survival since 
transplantation were compared between patients 
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according to their randomly assigned treatment 
group with the use of a stratified Mantel–
Haenszel test. In addition, a planned secondary 
analysis of outcomes was conducted with the use 
of Cox regression to adjust for the characteristics 
of the patients.
Covariates considered in the model-building 
process were transplantation center, year of trans-
plantation, conditioning regimen, GVHD pro-
phylaxis, recipient characteristics (age, sex, race, 
Karnofsky performance-status score [with scores 
ranging from 0 to 100 and higher scores indicat-
ing better performance status], diagnosis, disease 
stage, time from diagnosis to transplantation, sta-
tus with respect to cytomegalovirus [CMV] sero-
logic testing and coexisting diseases), donor char-
acteristics (age, sex, race, status with respect to 
CMV infection, and parity), and HLA matching. 
Post hoc HLA typing included high-resolution 
testing for HLA-A, B, C, and DRB1, and the degree 
of donor–recipient mismatching was defined with 
the use of these alleles, on the basis of work by 
Lee et al.17 Preplanned subgroup analyses of sur-
vival according to age, HLA matching, and disease 







Diagnosis — no. (%)
Acute myeloid leukemia 130 (47) 131 (48)
First complete remission 61 (22) 60 (22)
Second complete remission 32 (12) 32 (12)
Third or subsequent complete remission 5 (2) 3 (1)
Relapse 32 (12) 36 (13)
Acute lymphoblastic leukemia 61 (22) 56 (21)
First complete remission 21 (8) 30 (11)
Second complete remission 25 (9) 18 (7)
Third or subsequent complete remission 5 (2) 1 (0)
Relapse 10 (4) 7 (3)
Chronic myeloid leukemia 29 (10) 37 (14)
Chronic phase 20 (7) 24 (9)
Accelerated phase 6 (2) 7 (3)
Blast phase 3 (1) 6 (2)
Myelodysplastic syndrome 52 (19) 41 (15)
Refractory anemia, RARS, or RCMD 15 (5) 12 (4)
RAEB-1 or RAEB-2† 22 (8) 17 (6)
Other 15 (5) 12 (4)
Chronic myelomonocytic leukemia 4 (1) 4 (1)
Myelofibrosis 2 (1) 4 (1)
High-risk disease — no. (%)‡ 78 (28) 77 (28)
Age >40 yr — no. (%) 159 (57) 159 (58)
Male sex — no. (%) 168 (60) 146 (53)
White race — no. (%)§ 250 (90) 248 (91)
Karnofsky performance-status score ≥90% — no./total no. (%)¶ 172/240 (72) 154/228 (68)
Seropositivity for cytomegalovirus — no./total no. (%) 142/263 (54) 123/261 (47)
Conditioning regimen — no. (%)
Cyclophosphamide and total-body irradiation‖ 133 (48) 133 (49)
Cyclophosphamide and busulfan** 90 (32) 75 (27)
Fludarabine, busulfan, and antithymocyte globulin†† 39 (14) 40 (15)
Fludarabine and melphalan‡‡ 16 (6) 25 (9)
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risk were conducted with the use of an interac-
tion test in the Cox proportional-hazards model. 
The statistical analyses were performed with the 
use of SAS software, version 9.2 (SAS Institute).
R ESULT S
CHARACTERISTICS OF THE PATIENTS AND DONORS
The characteristics of the patients and donors are 
shown in Table 1, along with details of the treat-
ments. The bone marrow and peripheral-blood 
groups were well balanced with respect to age, 
sex, Karnofsky performance-status score, diag-
nosis, disease risk, positive result on serologic 
testing for CMV, and race. Patients were treated in 
48 transplantation centers in the United States and 
Canada. Donors were from 54 National Marrow 
Donor Program–affiliated donor centers in the 
United States, Canada, and Germany. The propor-
tion of donors who were fully matched for HLA-
A, B, C, and DRB1 and other donor characteris-






Stem Cells  
(N = 273)
GVHD prophylaxis — no. (%)
Cyclosporine and methotrexate 67 (24) 59 (22)
Tacrolimus and methotrexate 183 (66) 196 (72)
Other 28 (10) 18 (7)
Did not undergo transplantation — no. (%) 14 (5) 11 (4)
Antithymocyte globulin treatment — no./total no. (%)§§ 65/258 (25) 72/255 (28)
No. of donor mismatches at HLA-A, B, C, and DRB1 — no./total no. (%)¶¶
0 200/264 (76) 209/262 (80)
1 55/264 (21) 50/262 (19)
2 7/264 (3) 3/262 (1)
3 2/264 (1) 0/262
CD34+ cell dose per kilogram (×10−6)‖‖
Median 2.75 7.70
Interquartile range 1.94–4.53 5.43–11.28
* The CD34+ cell counts differed significantly between the two groups (P<0.001). There were no other significant between-
group differences. GVHD denotes graft-versus-host disease, RAEB refractory anemia with excess of blasts, RARS  
refractory anemia with ring sideroblasts, and RCMD refractory cytopenia with multilineage dysplasia.
† RAEB-1 is characterized by 5 to 9% blasts in bone marrow, and RAEB-2 by 10 to 19% blasts in bone marrow.
‡ High-risk disease includes acute myeloid leukemia in third or subsequent remission or not in remission, acute lympho-
blastic leukemia not in remission, the myelodysplastic syndrome with excess blasts in transformation, chronic myeloid 
leukemia in blast phase, and chronic myelomonocytic leukemia in any stage.
§ Race was determined by the investigators.
¶ Scores on the Karnofsky performance-status scale range from 0 to 100, with higher scores indicating better performance 
status.
‖ The required minimum doses for this conditioning regimen were cyclophosphamide at a dose of 120 mg per kilogram 
of body weight and a fractionated total-body irradiation of 12 Gy.
** The required minimum doses for this conditioning regimen were cyclophosphamide at a dose of 120 mg per kilogram 
given intravenously and busulfan at a dose of 14 mg per kilogram given orally or 11.2 mg per kilogram given intrave-
nously or an average targeted serum concentration greater than 600 ng per milliliter.
†† The required minimum doses for this conditioning regimen were fludarabine at a dose of 120 mg per square meter of 
body-surface area and busulfan at a dose of 8 mg per kilogram or 250 mg per square meter. The protocol did not 
specify a minimum dose for antithymocyte globulin.
‡‡ The required minimum doses for this conditioning regimen were fludarabine at a dose of 120 mg per square meter 
and melphalan at a dose of 140 mg per square meter.
§§ Data on treatment with antithymocyte globulin were not collected for patients who did not undergo transplantation. Data 
were also missing for several patients who did undergo transplantation.
¶¶ Data on donor HLA mismatch were not collected for patients who did not undergo transplantation.
‖‖ Data on CD34+ cell dose were missing for 121 patients (44%) in the bone marrow group and 25 (9%) in the peripheral-
blood group.
The New England Journal of Medicine 
Downloaded from nejm.org at WASHINGTON UNIV SCH MED MEDICAL LIB on April 16, 2014. For personal use only. No other uses without permission. 
 Copyright © 2012 Massachusetts Medical Society. All rights reserved. 
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 367;16 nejm.org october 18, 20121492
TREATMENT COMPLIANCE
More than 90% of the patients received a trans-
plant from the assigned graft source. Five percent 
of the patients randomly assigned to the bone 
marrow group and 4% of those randomly assigned 
to the peripheral-blood group did not undergo 
transplantation but were included in the intention-
to-treat analysis. The primary reason for not un-
dergoing transplantation (accounting for 84% of 
these patients) was relapse of cancer. Twelve pa-
tients (4%) randomly assigned to the bone marrow 
group received peripheral-blood stem cells owing 
to concern that a bone marrow harvest would de-
lay the transplantation (six patients) or because of 
a preference of the donor (four) or physician (two). 
One patient (<1%) randomly assigned to the pe-
ripheral-blood group received bone marrow be-
cause of donor preference. Overall, 98% of the 
patients received the conditioning regimen and 
GVHD prophylaxis chosen before randomization 
by the physician in charge of the transplantation.
INTENTION-TO-TREAT ANALYSIS
The primary end point was the overall survival 
rate at 2 years according to an intention-to-treat 
analysis. The 2-year overall survival rate in the 
peripheral-blood group was 51% (95% confidence 
interval [CI], 45 to 57), as compared with 46% 
(95% CI, 40 to 52) in the bone marrow group 
(stratified odds ratio, 1.20; 95% CI, 0.85 to 1.70; 
P = 0.29) (Fig. 1). The absolute difference in over-
all survival at 2 years was 5 percentage points 
(95% CI, −3 to 14).
SURVIVAL AND RELAPSE AFTER TRANSPLANTATION
The following analyses were restricted to patients 
who received the transplant. The rate of overall sur-
vival at 2 years after transplantation did not differ 
significantly in pointwise comparisons between 
the group randomly assigned to receive peripheral 
blood and the group assigned to receive bone mar-
row (estimated difference of 4 percentage points; 
95% CI, −4 to 13; P = 0.33) (Fig. 2A); neither did 
the rate of disease-free survival at 2 years (esti-
mated difference of 3 percentage points; 95% CI, 
−5 to 12; P = 0.38) (Fig. 2B). Mortality unrelated to 
relapse was similar at 2 years in the two treat-
ment groups (estimated difference of 2 percentage 
points; 95% CI, −6 to 9; P = 0.66) (Fig. 2C), as was 
the rate of relapse (estimated difference of 1 per-
centage point; 95% CI, −7 to 9; P = 0.74) (Fig. 2D). 
A sensitivity analysis that was performed with the 
use of multivariate Cox models with adjustment for 
age, disease risk, HLA matching, status with regard 
to the diffusing capacity of the lung for carbon 
monoxide, and conditioning regimen also showed 
similar results for overall survival and disease-free 
survival (P = 0.70 and P = 0.71, respectively). As ex-
pected, younger recipient age, low disease risk, and 
HLA matching of the donor (eight of the eight HLA 
alleles vs. seven of the eight) were associated with 
increased survival, but these variables had no inter-
action with stem-cell source (data not shown).
REPORTED ADVERSE EVENTS
The frequency of reported adverse events did not 
differ significantly between the two groups (Table 



























Figure 1. Survival after Randomization in the Intention-to-Treat Analysis.
The P value is from a stratified binomial comparison at the 2-year point. The 
P value from a stratified log-rank test was also not significant. A total of 75 pa-
tients in each group were still alive at 36 months.
Figure 2 (facing page). Outcomes after Transplantation, 
According to Study Group.
Panel A shows the rate of overall survival, and Panel B 
the rate of disease-free survival. Panel C shows the in-
cidence of death unrelated to relapse. Panel D shows 
the incidence of relapse. Panel E shows the incidence 
of neutrophil engraftment (>500 neutrophils per cubic 
millimeter), and Panel F the incidence of platelet engraft-
ment (>20,000 platelets per cubic millimeter, without 
platelet transfusion during the prior 7 days). Panel G 
shows the incidence of acute graft-versus-host disease 
(GVHD) of grades II to IV, and Panel H the incidence 
of chronic GVHD. P values for the between-group differ-
ences in overall survival (Panel A) and disease-free sur-
vival (Panel B) are from a stratified binomial comparison 
at the 2-year point; P values from stratified log-rank 
tests for survival and disease-free survival were also 
not significant. All other P values shown are from 
stratified log-rank tests.
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NEJM.org). The median duration of the first hos-
pitalization for the transplantation was 5 days 
shorter among patients who received peripheral-
blood stem cells than among those who received 
bone marrow (P<0.001), but the median number 
of days that transplant recipients were hospital-
ized during the first year of the study was similar 
in the two groups (37 days in each group, P = 0.41).
ENGRAFTMENT
Among patients randomly assigned to receive 
peripheral-blood stem cells, as compared with 
those randomly assigned to receive bone marrow, 
the median time to neutrophil engraftment was 
5 days shorter (P<0.001), and the median time to 
platelet engraftment was 7 days shorter (P<0.001) 
(Fig. 2E and 2F). Primary graft failure occurred in 
2% of the patients randomly assigned to receive 
peripheral-blood stem cells and in 6% of those 
randomly assigned to receive bone marrow; sec-
ondary graft failure occurred in 1% and 3% of 
patients, respectively. The total incidence of graft 
failure was 3% (95% CI, 1 to 5) in the peripheral-
blood group and 9% (95% CI, 6 to 13) in the bone 
marrow group (P = 0.002). The between-group dif-
ference in the incidence of all graft failures was 
7 percentage points (95% CI, 2 to 11; P = 0.002).
ACUTE AND CHRONIC GVHD
The rate of acute GVHD of grades II to IV (Fig. 
2G) and the rate of grade III or IV disease (data 
not shown) were similar in the two groups. The 
incidence of chronic GVHD at 2 years was sig-
nificantly higher in the peripheral-blood group 
than in the bone marrow group (53% [95% CI, 45 
to 61] vs. 41% [95% CI, 34 to 48], P = 0.01 by the 
stratified log-rank test) (Fig. 2H). The difference 
in the incidence of chronic GVHD at 2 years was 
12 percentage points (95% CI, 2 to 22). The pro-
portion of patients with extensive chronic GVHD 
was higher in the peripheral-blood group than in 
the bone marrow group (48% [95% CI, 42 to 54] 
vs. 32% [95% CI, 26 to 38], P<0.001). Among pa-
tients who were alive at 2 years, 57% of the pa-
tients in the peripheral-blood group were receiv-
ing immunosuppressive therapy, as compared with 
37% of those in the bone marrow group (P = 0.03).
CAUSES OF DEATH
There was no significant between-group differ-
ence in the proportion of deaths from infection or 
relapse. Deaths attributed to chronic GVHD were 
more common in the peripheral-blood group, 
whereas deaths attributed to graft failure were 
more common in the bone marrow group (P = 0.002) 
(Table 2). Acute and chronic GVHD were the pre-
dominant causes of deaths unrelated to relapse in 
both groups.
DISCUSSION
This large, multicenter, randomized trial did not 
show a significant survival difference between 
transplant recipients who received peripheral-
blood stem cells and those who received bone 
marrow from unrelated donors. Results were 
similar among HLA-mismatched pairs, recipi-
ents with advanced disease, and recipients older 
than 40 years of age, although this trial was not 
powered to detect potential differences within 
these subsets. Other transplantation outcomes, 
including relapse rates, mortality unrelated to re-
lapse, and rates of acute GVHD, were also similar 
with the two types of grafts, except that periph-
eral-blood stem-cell transplants were associated 
with better engraftment and bone marrow trans-
plants with less extensive chronic GVHD.
Our study was not powered to support firm 
conclusions on several issues of interest. However, it 
is possible to make some testable inferences from 
our results. These results show that although the 
two graft sources are associated with similar sur-
vival rates after transplantation, specific character-
istics of the patients may suggest the preferential 
use of peripheral-blood stem cells or bone marrow. 
Peripheral-blood stem cells may be recommended 
for patients at higher risk for graft failure.18-20 
For example, patients with malignant diseases 
who have never undergone cytotoxic chemothera-
py may be at increased risk for rejection of a bone 
marrow graft and might benefit from peripheral-
blood stem cells.21 Bone marrow may be recom-
mended for all other patients, especially those 
who are immunosuppressed owing to prior che-
motherapy, since they have a lower risk of graft 
rejection. For all patients, the use of bone mar-
row will decrease the risk of chronic GVHD.
Donor preference may also affect the choice of 
stem-cell source. In our trial, 30% of screened 
donors declined to undergo randomization, pre-
ferring one donation source over the other. Do-
nors who participated in the trial and were ran-
domly assigned to donate bone marrow reported 
more discomfort early after the donation, but 
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symptoms at 8 weeks were similar to those in 
the peripheral-blood stem-cell donors.22 The ac-
quisition costs are similar for peripheral-blood 
stem cells and bone marrow, according to the 
National Marrow Donor Program fee schedule, 
and therefore, graft-acquisition costs should not 
affect the choice of stem-cell source.12
The present study included patients with leu-
kemia or chronic myeloid disorders, 78% of whom 
were treated with myeloablative conditioning reg-
imens, and the results may not be generalizable to 
other clinical situations. For example, reduced-
intensity regimens, including very-low-dose, non-
myeloablative conditioning regimens, are now 
commonly used in patients older than 50 years 
of age and in those with serious coexisting dis-
eases.23 We did not find significant interactions 
between graft sources and the intensity of the 
conditioning regimen, but the range of intensity 
was narrow. Nonmyeloablative regimens were 
not allowed, and only 22% of the patients under-
went a reduced-intensity regimen. Nonmyeloab-
lative and reduced-intensity conditioning regi-
mens provide less intensive immunosuppression, 
and the stronger engraftment potential associated 
with peripheral-blood stem-cell transplantation 
could be advantageous in this situation.
Our results differ somewhat from the findings 
in studies of transplantation from HLA-identical 
siblings. In some of these studies, the use of 
peripheral-blood stem cells improved survival 
among patients with advanced disease, predomi-
nantly by decreasing the risk of relapse.24,25 This 
discrepancy may be due to differences in the study 
populations. Chronic myeloid leukemia is the dis-
ease most sensitive to the antileukemia effect of 
peripheral-blood stem-cell transplantation from 
siblings. Patients with chronic myeloid leukemia 
accounted for only 12% of our study population, 
as compared with 40 to 50% of patients in the 
sibling trials, probably because imatinib and 
other similar drugs had been approved for use in 
the interim.24-26 It is also possible that increased 
mortality from chronic GVHD among recipients 
of peripheral-blood stem cells from unrelated 
donors offsets the benefits associated with the 
more rapid and robust engraftment that occurs 
with peripheral-blood stem cells, as compared 
with bone marrow.27,28 Given the greater genetic 
disparity between unrelated donors and recipi-
ents, current regimens for GVHD prophylaxis 
may not adequately counteract the increased risk 
of GVHD that is associated with the higher num-
bers of T cells in peripheral-blood stem cells.
In conclusion, the rates of survival, relapse, 
and acute GVHD are similar with bone marrow 
and peripheral-blood stem-cell grafts from unre-
lated donors, but engraftment is better with pe-
ripheral-blood stem cells and the rate of chronic 
GVHD is lower with bone marrow. In addition 
to the relevance of these findings to the selec-
tion of a graft source for transplantation from 
unrelated donors, our results suggest that there 
is a need to develop transplantation approaches 
that decrease the risk of graft failure when bone 
marrow is used and that decrease the risks of 
acute and extensive chronic GVHD when either 
stem-cell source is used. Antilymphocyte globu-
lin has shown promise in preventing moderate-
to-severe chronic GVHD after transplantation 
from an unrelated donor.29,30 Alternatively, he-
matopoietic cells collected from bone marrow 
after donor treatment with growth factors may 
facilitate engraftment without increasing the risk 
of GVHD.9 Prospective randomized clinical trials 
are comparing this stem-cell source with un-
stimulated bone marrow or mobilized peripheral-
blood stem cells in recipients of transplants from 
HLA-identical siblings.
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Relapse 73 (50) 69 (48)
Infection 13 (9) 8 (6)
Graft failure 11 (8) 0
Acute GVHD 20 (14) 24 (17)
Chronic GVHD 14 (10) 30 (21)
Other 14 (10) 14 (10)
* P = 0.002 for the overall comparison between the groups. 
Percentages do not add up to 100 because of rounding.
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